Muscular Disorder TRIZ Cases
- Fetal Support Tissue for Infected Wound Healing
Amniotic membrane scaffolds enable infected wound treatment by providing antimicrobial barriers while stimulating endogenous repair mechanisms.
- Tenocyte-Seeded Bioscaffold for Rotator Cuff Repair
A tenocyte-seeded bioscaffold promotes tissue integration and healing in rotator cuff repair applications.
- Egg Yolk Powder FORTETROPIN for Muscle Protein Synthesis
FORTETROPIN egg yolk powder activates the mTOR pathway to increase muscle protein synthesis, avoiding testosterone side effects.
- Lycium barbarum glycopeptide for ALS treatment
Lycium barbarum glycopeptide replaces riluzole to extend survival and reduce inflammation in amyotrophic lateral sclerosis.
- SMN Protein Stabilizer and SMN2 Enhancer Combination
Merges splicing modulators, stabilizers, and enhancers into one composition to overcome insufficient single-agent efficacy in spinal muscular atrophy treatment.
- Hypoxia-Cultured MSCs for Cartilage Regeneration
Hypoxia-cultured mesenchymal stem cells promote cartilage regeneration while preventing osteoarthritis progression.
- CFTR Correctors for Striated Muscle Genetic Disorders
CFTR correctors rescue alpha-sarcoglycan and SERCA1 function, addressing liver toxicity risks from dantrolene.
- Anti-GDF-15 Antibodies Targeting GFRAL and RET Receptors
Specific antibodies inhibit GDF-15 signaling to suppress cancer cell proliferation.
- Suspension Seed Process for Recombinant AAV Vector Production
A suspension seed process produces recombinant AAV vectors in mammalian cells.
- IL-17 Antagonist and Regenerative Therapy for Aged Tissue Repair
Administering IL-17 antagonists alongside regenerative therapies reduces fibrosis and restores tissue repair capacity in aged subjects.
- Ketone Body Esters for Muscle Power and Reduced Gastric Discomfort
Esterified ketone bodies increase blood hydroxybutyrate levels while eliminating gastric discomfort from large oral volumes.
- PDGF-Loaded Porous Matrix for Tendon-Bone Attachment
A biocompatible porous matrix releases PDGF within 24 hours to resolve poor healing and high failure rates in tendon repairs.
- Kinase Inhibitors Targeting DUX4 for FSHD Treatment
Kinase inhibitors reduce DUX4 expression in muscle cells to treat facioscapulohumeral muscular dystrophy.
- Anti-VLA-4 Antibodies with Modified Fc Regions for Reduced Effector Function
Amino acid substitutions in the Fc region of anti-VLA-4 antibodies reduce adverse effector function and improve stability, addressing rapid clearance issues.
- Anti-Myostatin Antibody for FSHD Muscle Strength
An anti-myostatin antibody binds latent myostatin to increase muscle mass and strength.